Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

pi3k+mtor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (7) Bcl-2 Family (3) Biochemical Assay Reagents (1) Caspase (2) CDK (1) Drug-Linker Conjugates for ADC (1) EGFR (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (2) Mitochondrial Metabolism (3) MMP (1) mTOR (42) P-glycoprotein (1) p38 MAPK (2) Paraptosis (1) PI3K (43) PROTACs (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Telomerase (1) VEGFR (1)
By Research Areas:	Cancer (41) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (2)

By Targets:

ADC Payload (1)

Akt (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (7)

Bcl-2 Family (3)

Biochemical Assay Reagents (1)

Caspase (2)

CDK (1)

Drug-Linker Conjugates for ADC (1)

EGFR (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (1)

Ligands for Target Protein for PROTAC (1)

MDM-2/p53 (2)

Mitochondrial Metabolism (3)

MMP (1)

mTOR (42)

P-glycoprotein (1)

p38 MAPK (2)

Paraptosis (1)

PI3K (43)

PROTACs (1)

Ras (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Telomerase (1)

VEGFR (1)

By Research Areas:

Cancer (41)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12868

Bimiralisib 4 Publications Verification PQR309	PI3K mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR* inhibitor with IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and *mTOR, respectively. Bimiralisib is an mTORC1* and mTORC2 inhibitor.

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-111508

PI3K/mTOR Inhibitor-2 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for *mTOR* . Antitumor activity .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-151622

PI3K/mTOR Inhibitor-11 2 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active *PI3K/mTOR* inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-11080

PKI-179 1 Publications Verification	PI3K mTOR	Cancer
PKI-179 is a potent and orally active dual *PI3K/mTOR* inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for *PI3K-α, PI3K-β, PI3K-γ, PI3K-δ* and *mTOR, respectively. PKI-179 also exhibits activity over E545K* and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo .

HY-12763

GNE-317 2 Publications Verification	PI3K mTOR	Cancer
GNE-317 is a *PI3K/mTOR* inhibitor, is able to cross the blood-brain barrier (BBB).

HY-128333

PI3K/mTOR Inhibitor-4	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-131015

HaXS8	Biochemical Assay Reagents	Others
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective PI3Kα inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-176854

PI3K/mTOR-IN-18	PI3K mTOR	Cancer
PI3K/mTOR-IN-18 (Compound 12) is a highly selective dual *PI3K/mTOR* inhibitor. PI3K/mTOR-IN-18 shows antitumor effects via competitive binding to PI3Kα (K_i=0.130 nM) and mTOR (K_i=0.111 nM). PI3K/mTOR-IN-18 blocks the PI3K/AKT/mTOR pathway and inhibits tumor cell proliferation (IC₅₀=144 nM). PI3K/mTOR-IN-18 is promising for research of solid tumors (e.g., breast, NSCLC) .

HY-109633

PI3K/mTOR-IN-23	mTOR PI3K	Cancer
PI3K/mTOR-IN-23 is a dual inhibitor of *PI3K* and *mTOR* with IC₅₀ values of 49 and 41 nM. PI3K/mTOR-IN-23 inhibits cancer cells proliferation .

HY-112602

PI3K/mTOR Inhibitor-1	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual *PI3K/mTOR* inhibitor with IC₅₀s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and *mTOR*, respectively . Antitumor activity .

HY-155066

FD274	PI3K mTOR Apoptosis	Cancer
FD274 is a highly potent *PI3K/mTOR* dual inhibitor with IC₅₀s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 arrests HL-60 cell cycle at G1 phase and increases apoptosis. FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .

HY-152238

PI3K/mTOR Inhibitor-12	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-12 is a potent, orally active and selective *PI3K/mTOR* inhibitor with IC₅₀ values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .

HY-147613

PI3K/mTOR Inhibitor-6	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .

HY-147614

PI3K/mTOR Inhibitor-7	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC₅₀ values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .

HY-170656

PI3K/mTOR Inhibitor-17	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-17 (compound 5nh) is a potent inhibitor of *PI3K/mTOR, with the inhibitor of 0.45 and 2.9 nM for PI3Kα and mTOR, respectively. PI3K/mTOR* Inhibitor-17 plays an important role in cancer research .

HY-141476

PI3K/mTOR Inhibitor-3	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent *PI3K* and *mTOR* dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity .

HY-156445

PI3K/mTOR Inhibitor-14	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-14 (compound Y-2) is a potent *PI3K* and *mTOR* dual inhibitor with IC₅₀s of 171.4 nM and 10.1 nM, respectively. PI3K/mTOR Inhibitor-14 has antitumor activities .

HY-109633A

PI3K/mTOR-IN-23 dihydrochloride	mTOR PI3K	Cancer
PI3K/mTOR-IN-23 dihydrochloride is a dual inhibitor of *PI3K* and *mTOR* with IC₅₀ values of 49 and 41 nM. PI3K/mTOR-IN-23 dihydrochloride inhibits cancer cells proliferation .

HY-146200

PI3K/mTOR Inhibitor-8	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-8 (Compound 18b) is a *PI3K* and *mTOR* dual inhibitor with IC₅₀ values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase .

HY-179155

PI3K/mTOR-IN-19	PI3K mTOR Apoptosis Bcl-2 Family MDM-2/p53 Telomerase Mitochondrial Metabolism	Inflammation/Immunology Cancer
PI3K/mTOR-IN-19 is an orally active, potent, selective *PI3K* (IC₅₀ = 4.23 nM) and *mTOR* (IC₅₀ = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer .

HY-146016

PI3K/mTOR Inhibitor-5	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual *PI3K* and *mTOR* inhibitor, with IC₅₀ values of 86.9 nM and 14.6 nM, respectively .

HY-179457

CC-11	PI3K mTOR Akt HSP	Cancer
CC-11 is an orally active small molecule drug conjugate (SMDC) that links the *PI3K/mTOR* inhibitor with the extracellular heat shock protein 90 (EHSP90) targeting ligand through a cleavable linker. CC-11 exhibits strong HSP90 binding activity (IC₅₀ = 15 nM) and inhibits PI3Kα kinase activity (IC₅₀ = 0.54 nM). CC-11 has anti-proliferative activity against colon cancer cells. CC-11 shows significant efficacy in the HCT-116 xenograft tumor model. CC-11 can be used for research on colon cancer .

HY-147285

PI3K/mTOR Inhibitor-9	mTOR PI3K	Neurological Disease
PI3K/mTOR Inhibitor-9 (Compound 1) is a potent *mTOR* and *PI3K* inhibitor with IC₅₀ values of 38 nM, 6.6 μM, 6.6 μM and 0.8 μM against mTOR (phospho-S6 cellular assay), PI3Kα, PI3Kγ and PI3Kδ, respectively .

HY-130133

DHW-221	PI3K mTOR Akt Apoptosis Paraptosis p38 MAPK Mitochondrial Metabolism P-glycoprotein CDK MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
DHW-221 is a potent orally active dual *PI3K/mTOR* inhibitor, exhibiting low nanomolar potency against all four Class I PI3K isoforms and mTOR (PI3Kα, IC₅₀ = 0.50 nM; PI3Kβ, IC₅₀ = 1.9 nM; PI3Kγ, IC₅₀ = 1.8 nM; PI3Kδ, IC₅₀ = 0.74 nM; mTOR, IC₅₀ = 3.9 nM). DHW-221 exerts antitumor effects by blocking the *PI3K/Akt/mTOR* pathway and inducing mitochondrial apoptosis and paraptosis (via Endoplasmic Reticulum (ER) stress and MAPK signaling) and arrests cell cycle, thereby inhibiting cell migration, invasion and angiogenesis. DHW-221 inhibits tumor growth in both the A549/Taxol (HY-B0015) and the HCC827 xenograft mouse models. DHW-221 can be used for non-small cell lung cancer (NSCLC), colon and breast cancer research ^[3].

HY-174855

PI3K/mTOR-IN-17	PI3K mTOR Apoptosis Bcl-2 Family MDM-2/p53 Caspase	Cancer
PI3K/mTOR-IN-17 is a dual PI3K and mTOR inhibitor with IC₅₀ values of 1.21 μM (PI3K), and 0.21 μM (mTOR). PI3K/mTOR-IN-17 induces cells caspase-mediated apoptosis by arresting their growth in the G1-phase. PI3K/mTOR-IN-17 upregulates the levels of caspases-3, 7, 8, and 9, p53 expression and Bax/Bcl-2 ratio. PI3K/mTOR-IN-17 suppresses the PI3K/mTOR signaling pathway. PI3K/mTOR-IN-17 can be used for research of cancer, such as non-small cell lung cancer (NSCLC) .

HY-203618

PI3K/mTOR ligand-1	Ligands for Target Protein for PROTAC mTOR PI3K	Cancer
PI3K/mTOR ligand-1 is a ligand for the target protein of PROTAC (PI3K/mTOR). PI3K/mTOR ligand-1 can be used to synthesize GP262 (HY-180261) .

HY-179464

CC-M-1	PI3K mTOR	Cancer
CC-M-1 is a potent and selective *PI3K/mTOR* inhibitor. CC-M-1 inhibits PI3Kα/β/γ/δ and *mTOR* with IC₅₀ values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. CC-M-1 inhibits the proliferation of colorectal cancer cell lines, including HCT-116 (IC₅₀ = 0.38 μM) and HT-29 (IC₅₀ = 1.70 μM). CC-M-1 can be used for colorectal cancer (CRC) research .

HY-11080A

PKI-179 hydrochloride 1 Publications Verification	PI3K mTOR	Cancer
PKI-179 hydrochloride is a potent and orally active dual *PI3K/mTOR* inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for *PI3K-α, PI3K-β, PI3K-γ, PI3K-δ* and *mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K* and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo .

HY-185456

PI3K/mTOR-IN-21	ADC Payload PI3K mTOR	Cancer
PI3K/mTOR-IN-21 is a potent dual *PI3K/mTOR* inhibitor that exhibits favorable overall properties.

HY-183327

PI3K/mTOR-IN-22	PI3K mTOR Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism Bcl-2 Family Caspase	Cancer
PI3K/mTOR-IN-22 is an orally active *PI3K/mTOR* kinase dual inhibitor with IC₅₀ values of 400.5 nM and 8.2 nM. PI3K/mTOR-IN-22 downregulates phosphorylation of the AKT and mTOR, upregulates pro-apoptotic proteins Bax and caspase-3 and downregulates anti-apoptotic protein Bcl-2. PI3K/mTOR-IN-22 exhibits antiproliferative activity against cancer cells, induces apoptosis and ROS production, and reduces mitochondrial membrane potential. PI3K/mTOR-IN-22 exhibits antitumor activity in breast cancer mice models .

HY-180556

PI3K/mTOR-IN-20	mTOR PI3K	Inflammation/Immunology
PI3K/mTOR-IN-20 is a selective dual *PI3K/mTOR* inhibitor. PI3K/mTOR-IN-20 demonstrates nanomolar antiproliferative effects with IC₅₀s of 0.380 and 0.090 μM for MRC-5 and Mlg2908 cells. PI3K/mTOR-IN-20 reduces Ashcroft scores, hydroxyproline content, collagen deposition, and downregulates fibrosis-related proteins, while restoring lung architecture in a Bleomycin-induced pulmonary fibrosis model. PI3K/mTOR-IN-20 shows a favorable safety profile with steady weight recovery and no distinct liver or kidney toxicity. PI3K/mTOR-IN-20 can be used for fetal lung fibroblasts research .

HY-147966

HDAC-IN-43	HDAC PI3K mTOR	Cancer
HDAC-IN-43 is a potent HDAC 1/3/6 inhibitor with IC₅₀ values of 82, 45, and 24 nM, respectively. HDAC-IN-43 is a weak *PI3K/mTOR* inhibitors with IC₅₀ values of 3.6 and 3.7 μM, respectively. HDAC-IN-43 shows broad anti-proliferative activity .

HY-185457

*BrAC-GGFG-Aminal-PI3K/mTOR-IN-21*	Drug-Linker Conjugates for ADC PI3K mTOR	Cancer
BrAC-GGFG-Aminal-PI3K/mTOR-IN-21 is a conjugate of PI3K/mTOR-IN-21 (HY-185456) and Linker.

HY-168919

KRASG12C IN-16	Ras Apoptosis p38 MAPK PI3K mTOR	Cancer
KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRAS ^G12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and *PI3K/mTOR* signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer .

HY-139832

MCX 28	PI3K mTOR	Cancer
MCX 28, a triple *PI3K/mTOR/PIM* inhibitor, displays low nanomolar activity.

HY-100398R

PF-04979064 (Standard)	PI3K Reference Standards mTOR	Cancer
PF-04979064 (Standard) is the analytical standard of PF-04979064 (HY-100398). This product is intended for research and analytical applications. PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with Kis of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-180261

GP262	PROTACs mTOR PI3K Apoptosis	Cancer
GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and *mTOR* with DC₅₀ values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells. GP262 induces degradation of p110α and p110γ with a DC₅₀ of 227.4 and 42.23 nM. GP262 efficient modulates the PI3K/AKT/mTOR pathway, achieving degradation through the ubiquitin-proteasome system (UPS). GP262 also exhibits robust antiproliferative activity and induces apoptosis in vitro. GP262 exhibits tumor growth suppression capability and biosafety profile. GP262 can be used for leukemia and triple-negative breast cancer (TNBC) .

HY-185460

Pertuzumab-LD3	Antibody-Drug Conjugates (ADCs) EGFR PI3K mTOR	Cancer
Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonal antibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer.

HY-181710

LASSBio-2337	mTOR PI3K	Cancer
LASSBio-2337 is a dual pan-PI3K/mTOR inhibitor with an mTOR IC₅₀ of 5.8 μM.LASSBio-2337 functionally modulates mTOR and all PI3K isoforms.LASSBio-2337 acts as a cytotoxic agent in leukemia cells, including multidrug-resistant populations.LASSBio-2337 spares nontumor human peripheral blood mononuclear cells.LASSBio-2337 displays moderate PAMPA-GIT permeability.LASSBio-2337 shows low metabolic stability in rat liver microsomes.LASSBio-2337 is aqueous insoluble.LASSBio-2337 can be used for the research of acute lymphoblastic leukemia, chronic myelogenous leukemia, breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

pi3k+mtor

Inhibitors & Agonists